Meiselman, Denlea, Packman, Carton & Eberz P.C. is currently investigating a potential class action against Merck & Co. ("Merck") concerning the drugs Temodar, PegIntron, and Intron A. As recently reported by the Wall Street Journal (August 9, 2011), the Justice Department has issued a subpoena to Merck as part of a criminal investigation into the marketing and selling activities relating to the three drugs. Temodar is prescribed for brain tumors; PegIntron is prescribed for hepatitis C; and Intron A is prescribed for certain cancers and other conditions. From 2004 to 2009, the drugs were marketed by Schering-Plough, which Merck subsequently acquired. Sales figures for the three drugs are in the hundreds of millions of dollars.
If you or someone you know has been prescribed Temodar, PegIntron or Intron A, you may have been a victim of unfair marketing activities. Similarly, if you are a physician who issued prescriptions for those drugs, you may also have been the victim of deceptive sales practices. Please contact us as soon as possible to discuss your legal options.